Rapport Therapeutics released compelling Phase II results for RAP-219, a TARPγ8-specific AMPAR negative allosteric modulator aimed at treating drug-resistant focal onset seizures. The trial showed a 78% median reduction in clinical seizures and marked decreases in electrographic seizure activity, exceeding prior expectations. These results have propelled the company’s share price dramatically and fueled plans to initiate Phase III trials in 2026. The data suggest RAP-219 as a potential best-in-class therapy with favorable efficacy and tolerability profiles.